Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 20/20 | 1.00 |
| ▸ | ESR2 | Q92731 | 19/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 0.98 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.98 |
| ▸ | LMNA | P02545 | 2/20 | 0.98 |
| ▸ | TP53 | P04637 | 2/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.98 |
| ▸ | MAPT | P10636 | 2/20 | 0.98 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.98 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.98 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.98 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.98 |
| ▸ | PLD2 | O14939 | 1/20 | 0.98 |
| ▸ | KDM1A | O60341 | 1/20 | 0.98 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.98 |
| ▸ | USP2 | O75604 | 1/20 | 0.98 |
| ▸ | C5 | P01031 | 1/20 | 0.98 |
| ▸ | FYN | P06241 | 1/20 | 0.98 |
| ▸ | PGR | P06401 | 1/20 | 0.98 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ly-117018 SCHEMBL4884822 | 1.00 | ESR1 (1.00) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Raloxifene SCHEMBL29362592 | 0.99 | ESR1 (1.00) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Raloxifene SCHEMBL6144 | 0.99 | ESR1 (1.00) | ESR1ESR2MEN1ALDH1A1LMNA | |
| SCHEMBL5821250 | 0.99 | ESR1 (1.00) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Raloxifene SCHEMBL9145135 | 0.99 | ESR1 (1.00) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Raloxifene SCHEMBL3162158 | 0.99 | ESR1 (1.00) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Ly-117018 SCHEMBL7080240 | 0.99 | ESR1 (0.98) | ESR1ESR2MEN1ALDH1A1LMNA | |
| SCHEMBL6595498 | 0.99 | ESR1 (0.98) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL9201404 | 0.98 | ESR1 (1.00) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Raloxifene SCHEMBL1665344 | 0.98 | ESR1 (0.98) | ESR1ESR2MEN1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 157 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3380124-B1 | CONJUGATES COMPRISING SELF-IMMOLATIVE GROUPS AND METHODS RELATED THERETO | LEGOCHEM BIOSCIENCES INC (KR) | 2024-04-03 | — | — | EP | claimed |
| US-12636377-B2 | Anti-EDB antibodies and antibody-drug conjugates | PFIZER, INC. (US) | 2026-05-26 | — | — | US | disclosed |
| WO-2026102349-A1 | ANTI-INTERLEUKIN-23 RECEPTOR VHH ANTIBODIES AND USES THEREOF | GENENTECH, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| EP-4285998-B1 | GLYCOLIPIDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR USE IN THERAPY | UNIV NOTTINGHAM (GB) | 2026-05-06 | — | — | EP | disclosed |
| EP-4722250-A2 | FORMULATIONS OF ANTI-PD1 ANTIBODIES | Formycon AG (DE) | 2026-04-08 | — | — | EP | disclosed |
| EP-4709484-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | GENENTECH, INC. (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4180812-B1 | METHOD FOR MONITORING THE RESPONSE TO NEOADJUVANT THERAPY FOR BREAST CANCER | UNIV FREIBURG ALBERT LUDWIGS (DE) | 2026-02-25 | — | — | EP | disclosed |
| US-20260028420-A1 | ANTI-TUMOR ANTIBODIES | IMMUNOME INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-12528848-B2 | Tumor-specific neoantigens and methods of using the same | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY | 2026-01-20 | — | — | US | disclosed |
| US-20260009000-A1 | METHODS FOR TRANSDUCING IMMUNE CELLS | ALLOGENE THERAPEUTICS, INC. (US) | 2026-01-08 | — | — | US | disclosed |
| US-20220168293-A1 | TIME TO RESOLUTION OF AXITINIB-RELATED ADVERSE EVENTS | PFIZER INC. (US) | 2022-06-02 | — | — | US | disclosed |
| EP-3999507-A1 | IMIDAZO[4,5-C]PYRIDINE DERIVATIVES AS TOLL-LIKE RECEPTOR AGONISTS | Pfizer Inc. (US) | 2022-05-25 | — | — | EP | disclosed |
| WO-2022098638-A2 | DOSING FOR TREATMENT WITH ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODIES | GENENTECH, INC. (US) | 2022-05-12 | — | — | WO | disclosed |
| EP-3355902-B1 | COMBINATION OF A PD-1 AXIS BINDING ANTAGONIST AND AN ALK INHIBITOR FOR TREATING ALK-NEGATIVE CANCER | MERCK PATENT GMBH (DE) | 2022-04-13 | — | — | EP | disclosed |
| EP-3976043-A1 | COMBINATION THERAPIES USING CDK INHIBITORS | Pfizer Inc. (US) | 2022-04-06 | — | — | EP | disclosed |
| EP-3976040-A1 | PD-1 AXIS BINDING ANTAGONIST TO TREAT CANCER WITH GENETIC MUTATIONS IN SPECIFIC GENES | Ares Trading S.A. (CH) | 2022-04-06 | — | — | EP | disclosed |
| EP-3976090-A1 | COMBINATION THERAPIES USING CDK INHIBITORS | Pfizer Inc. (US) | 2022-04-06 | — | — | EP | disclosed |
| EP-3972432-A1 | PHARMACEUTICAL FORMULATIONS AND METHODS FOR DELIVERING A THERAPEUTIC, DIAGNOSTIC, OR IMAGING AGENT TO CD206 | Syracuse University (US) | 2022-03-30 | — | — | EP | disclosed |
| WO-2022050954-A1 | DOSING FOR TREATMENT WITH ANTI-TIGIT AND ANTI-PD-L1 ANTAGONIST ANTIBODIES | GENENTECH, INC. (US) | 2022-03-10 | — | — | WO | disclosed |
| WO-2021252977-A9 | METHODS AND COMPOSITIONS FOR CANCER IMMUNOTHERAPY | GENENTECH, INC. (US) | 2022-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12528848-B2 | Tumor-specific neoantigens and methods of using the same | FURIN, CPSF1, NUDT21 | ESR1 861/4885ESR2 942/4885MEN1 1264/4885 |
| US-12636377-B2 | Anti-EDB antibodies and antibody-drug conjugates | FN1, F13B, EDNRB | ESR1 262/4885ESR2 443/4885MEN1 2162/4885 |
| US-20260028420-A1 | ANTI-TUMOR ANTIBODIES | B4GALT1, ST6GAL1, GALNT3 | ESR1 4544/4885ESR2 4728/4885MEN1 2860/4885 |
| US-20260009000-A1 | METHODS FOR TRANSDUCING IMMUNE CELLS | PBK, ICOS, NFATC1 | ESR1 1783/4885ESR2 3573/4885MEN1 4549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.